WO2024018350 - TREATMENT OF AIHA WITH BAFF OR BAFF RECEPTOR INHIBITORY ANTIBODIES
National phase entry:
Publication Number
WO/2024/018350
Publication Date
25.01.2024
International Application No.
PCT/IB2023/057257
International Filing Date
17.07.2023
Title **
[English]
TREATMENT OF AIHA WITH BAFF OR BAFF RECEPTOR INHIBITORY ANTIBODIES
[French]
TRAITEMENT DE L'AHAI AVEC DES ANTICORPS INHIBITEURS DE BAFF OU DE RÉCEPTEUR DE BAFF
Applicants **
NOVARTIS AG
Inventors
BEZLYAK, Vladimir
LAWNICZEK, Tomasz
MARTURANO, Emerenziana
STANKOVIC, Miona
URBAN, Patrick
Priority Data
63/368,825
19.07.2022
US
63/384,051
16.11.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4596 | |
| EPO | Filing, Examination, Granting | 87995 | |
| Japan | Filing, Examination, Granting | 4762 | |
| South Korea | Filing, Examination, Granting | 7212 | |
| USA | Filing, Examination, Granting | 20340 |
Total:
124,905
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure relates to a molecule that inhibits BAFF pathway, particularly an antibody or a binding fragment thereof, particularly an anti-BAFF-R antibody, e.g. ianalumab, for use in the treatment of autoimmune hemolytic anemia (AIHA), in particular, warm autoimmune hemolytic anemia (wAIHA).[French]
L'invention concerne une molécule qui inhibe la voie BAFF, en particulier un anticorps ou un fragment de liaison de celui-ci, en particulier un anticorps anti-BAFF-R, par exemple l'ianalumab, destinée à être utilisée dans le traitement de l'anémie hémolytique auto-immune (AHAI), en particulier, de l'anémie hémolytique auto-immune à anticorps chauds (AHAI-AC).